- Patients with schizophrenia taking 3 or more classes of psychiatric drugs are at significantly greater risk for type 2 diabetes.
Why this matters
- The results need to be verified by further research but suggest that increases in monotherapy dose or switching to a new drug may carry less T2D risk than combination therapies.
- The Genetic Overlap between Metabolic and Psychiatric disease study was a nested case-control study on hospitalized patients with schizophrenia (with type 2 diabetes, n=536; without type 2 diabetes, n=854).
- Funding: Wellcome.
- Treatment with ≥3 psychiatric drugs (antipsychotic+≥2 psychiatric medications) vs first-generation antipsychotics alone was significantly associated with greater risk for type 2 diabetes (aOR, 1.81; P=.003).
- No significant association between drug use and risk for T2D was noted with:
- 2-drug combinations (antipsychotic+≥1 psychiatric medications; aOR, 0.98; P=.885) and
- second-generation antipsychotics (aOR, 1.27; P=.259).
- Retrospective medication information up to 6 months before the study was used.
- Effect of previous treatment regimens not known.
Coauthored with Chitra Ravi, MPharm